Conclusion: These results suggest that RORalpha protects kidney from I/R damage through transcriptional activation of HIF-1 and represents a potential therapeutic target for AKI. http://dx.
group. In addition, we also observed more obvious inhibition of renal tubular cell apoptosis and promotion of proliferation in -1 h and 0 h groups compared with other groups. Consistent with the improvement above, the viability of implanted MSCs also increased in -1 h and 0 h groups. Conclusion: MSCs transplanted 1 h before reperfusion or immediately after reperfusion produce the most dramatic improvement in renal function and morphology in rat model of renal I/R injury. It is the optimal timing to transplant MSCs in IRI before the inflammatory response is established. Objective: We collected the epidemiological data of patients with AKI from 2009 to 2013 in order to explore the influencing factors of changes of epidemiology after cardiac sugery. Methods: Clinical data, which included demographic data of preoperative, intraoperative, postoperative, were prospectively collected in our hospital from January 2009 to December 2013. The main endpoint was poor prognosis including overall mortality and abandon of treatment. The second point was renal outcome. Results: A total of 11693 patients enrolled, including 6637 males and 5056 females. The overall AKI incidence was 34.5%. The AKI incidence increased during the five years from 34.2% to 36.5% (P < 0.05). There was no significantly statistical differences in AKI-RRT incidences during the 5 years (P Z 0.360). The hospital mortality of AKI decreased from 6.3% in 2009 to 3.8% in 2013. The incidence of poor prognosis in AKI were 8.3%, 7.5%, 6.8%, 5.1%, 8.0% (P Z 0.196). The mortality of AKI-RRT decreased from 47.1% in 2009 to 29.5% in 2013 (P Z 0.230). The incidence of poor prognosis in RRT decreased from 66.7% to 57.4% (P Z 0.825). Multivariate logistic regression analysis showed that male, old age, body mass index (every additional 5 kg/ m 2 ), hypertension, chronic heart failure, pre-operative serum creatinine > 115 mmol/L, CPB (every additional 30 minutes) were the risk factors of AKI after cardiac surgery. Conclusion: The incidence of AKI after cardiac surgery increased from 2009 to 2013 and the rate of poor prognosis did not change. Results: A total of 297 patients were enrolled. The hospital mortality was 64.7%. The %FO at RRT initiation and at the end of RRT in the death group was significantly higher than in survival group [5.0 (2.4, 9. 3) vs. 2.5 (0.2, 5.8)%; 8.4 (3.6, 14.2) vs. 3.9 (0.4, 9.2)%; P < 0.05]. Among AKI-RRT patients, the incidence of low cardiac output syndrome (LCOS) in the death group was significantly higher than in the survival group (66.0% vs. 20.0%, P < 0.01). Hospital mortality in the LCOS group was significantly higher than in the non-LCOS group (81.9% vs. 56.7%, P < 0.001). The %FO at RRT initiation and at the end of RRT in the LCOS group were higher than in the non-LCOS group (P < 0.05). Conclusion: Among AKI-RRT patients after cardiac surgery, absolute FO and %FO in the death group were higher than in the survivor group. Fluid overload and LCOS increased the risk of mortality. Objective: Recent studies indicate that Smad7 plays a protective role in many chronic kidney diseases by attenuating both renal fibrosis and inflammation. However, role of Smad7 in acute kidney injury (AKI) remains unclear, which was investigated in this study in a mouse model of AKI induced in Smad 7 knockout (KO) mice. Methods: Ischemia/reperfusion mouse model of AKI was induced in Smad7 KO mice and their WT (wild type) littermates by bilaterally clamping their renal arteries with vascular clip for 45 min. In addition, a rescued study was also performed in Smad7 KO mice by Smad7 gene transfer locally into the kidney using a non-invasion ultrasound-microbubble technique. Effect of disrupted or overexpressed renal Smad7 on renal function and tubular epithelial cell regeneration was investigated. Results: Compared to WT mice, Smad7 KO mice developed more severe renal damage as demonstrated by a significant increase in serum creatinine and tubular necrosis at 48 hour. Future study revealed that cell proliferation, detected by BrdU incorporation and PCNA expression, was greatly suppressed in Smad7 KO mice after AKI. This was associated with enhanced activation of Smad3 and up-regulation of CDK inhibitor p21 and p27, resulting in inactivation of cell cycling by suppressing CDK2 and Cyclin E. In contrast, restored Smad7 locally in the kidney of Smad7 KO mice attenuated the progression of AKI by reversing Smad3-dependent p21/p27-induced inhibition of CKD2/Cyclin E-mediated tubular cell proliferation. Conclusion: Smad7 plays a protective role in the recovery process of AKI via mechanism of inactivating TGF-b/Smad3-p21/p27-dependent inhibition of CKD2/Cyclin pathway. Thus, Smad7 may be a novel therapeutic agent for AKI.
